Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: Establishment of a modified allergic dermatitis model in mouse ear lobes by application of 12-O-tetradecanoyl phorbol 13-acetate: Putative involvement of thymic stromal lymphopoietin and roles of histamine

Journal of Pharmacological Sciences

Volumn 110, Issue 3, 2009, Pages 245-250

  Hirasawa, Noriyasu ^a   Ohsawa, Yuhsuke ^a   Ishihara, Kenji ^a,c   Seyama, Toshio ^b   Hong, JangJa ^a,b   Ohuchi, Kazuo ^a,b  

^a TOHOKU UNIVERSITY   (Japan)

^b YASUDA WOMEN'S UNIVERSITY   (Japan)

^c IBARAKI UNIVERSITY   (Japan)

Author keywords

12 O tetradecanoylphorbol 13 acetate; Allergic dermatitis; Allergic inflammation; Histamine; Picryl chloride; Thymic stromal lymphopoietin

Indexed keywords

1 (5 CHLORO 2 INDOLYLCARBONYL) 4 METHYLPIPERAZINE; CIMETIDINE; CYCLOSPORIN A; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H4 RECEPTOR ANTAGONIST; MEPYRAMINE; PHORBOL 13 ACETATE 12 MYRISTATE; TACROLIMUS; THIOPERAMIDE; THYMIC STROMAL LYMPHOPOIETIN;

CONFERENCE PAPER; DELAYED HYPERSENSITIVITY; DISEASE COURSE; DRUG INHIBITION; EAR DISEASE; EAR LOBE; EOSINOPHIL; NONHUMAN; SKIN ALLERGY; TH2 CELL;

EID: 67749111697     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09R03FM     Document Type: Conference Paper

References (27)

1. Kiehl P, Falkenberg K, Vogelbruch M, Kapp A. Tissue eosinophilia in acute and chronic atopic dermatitis: a morphometric approach using quantitative image analysis of immunostaining. Br J Dermatol. 2001;145:720-729. (Pubitemid 33078342)
2. Novak N, Bieber T, Leung DYM. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol. 2003;112:S128-S139. (Pubitemid 37550029)
3. Kitagaki H, Ono N, Hayakawa K, Kitazawa T, Watanabe K, Shiohara T. Repeated elicitation of contact hypersensitivity induces a shift in cutaneous cytokine milieu from a T helper cells type 1 to a T helper cell type 2 profile. J Immunol. 1997;159:2484-2491. (Pubitemid 127681044)
4. Harada D, Takada C, Tsukumo Y, Takaba K, Manabe H. Analyses of a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application. J Dermatol Sci. 2005;37:159-167.
5. Kitagaki H, Fujisawa S, Watanabe K, Hayakawa K, Shiohara T. Immediate-type hypersensitivity response followed by a late reaction is induced by repeated epicutaneous application of contact sensitizing agents in mice. J Invest Dermatol. 1995;105: 749-755. (Pubitemid 26006351)
6. Yokozeki H, Wu MH, Sumi K, Igawa K, Miyazaki Y, Katayama I, et al. Th2 cytokines, IgE and mast cells play a crucial role in the induction of para-phenylenediamine-induced contact hypersensitivity in mice. Clin Exp Immunol. 2003;132:385-392.
7. Huang CH, Kuo IC, Xu H, Lee YS, Chua KY. Mite allergen induces allergic dermatitis with concomitant neurogenic inflammation in mouse. J Invest Dermatol. 2003;121:289-293. (Pubitemid 36969902)
8. Matsuda H, Watanabe N, Geba GP, Sperl J, Tsudzuki M, Hiroi J, et al. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol. 1997;9:461-466. (Pubitemid 27113270)
9. Gao XK, Nakamura N, Fuseda K, Tanaka H, Inagaki N, Nagai H. Establishment of allergic dermatitis in NC/Nga mice as a model for severe atopic dermatitis. Biol Pharm Bull. 2004; 27:1376-1381. (Pubitemid 41701678)
10. Tomimori Y, Tanaka Y, Goto M, Fukuda Y. Repeated topical challenge with chemical antigen elicits sustained dermatitis in NC/Nga mice in specific-pathogen-free condition. J Invest Dermatol. 2005;124:119-124. (Pubitemid 40100959)
11. Grabbe S, Steinert M, Mahnke K, Schwarz A, Lugar TA, Shuwarz T. Dissection of antigenic and irritative effects of epicutaneously applied haptens in mice. J Clin Invest. 1996;98: 1158-1164.
12. Hirasawa N, Ohsawa Y, Katoh G, Shibata K, Ishihara K, Seyama T, et al. Modification of picryl chloride-induced allergic dermatitis model in mouse ear lobes by 12-O-tetradecanoylphorbol 13-acetate, and analysis for roles of histamine in the modified model. Int Arch Allergy Immunol. 2008; 148:279-288.
13. Satoh T, Chen QJ, Sasaki G, Yokozeki H, Katayama I, Nishioka K. Cyclophosphamide-induced blood and tissue eosinophilia in contact sensitivity: mechanism of hapten-induced eosinophil recruitment into the skin. Eur J Immunol. 1997;27:85-91. (Pubitemid 27046062)
14. Sims JE, Williams DE, Morrissey PJ, Garka K, Foxworth D, Price V, et al. Molecular cloning and biological characterization of a novel murine lymphoid growth factor. J Exp Med. 2000; 192:671-680. (Pubitemid 30688796)
15. Soumelis V, Reche PA, Kanzler H, Yuan W, Edward G, Homey B, et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002; 3:673-680. (Pubitemid 34752477)
16. Yoo J, Omori M, Gyarmati D, Zhou B, Aye T, Brewer A, et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med. 2005;202:541-549. (Pubitemid 41186952)
17. Omori M, Ziegler S. Induction of IL-4 expression in CD4+ T cells by thymic stromal lymphopoietin. J Immunol. 2007;178: 1396-1404. (Pubitemid 46154610)
18. McIlroy A, Caron G, Blanchard S, Fremaux I, Duluc D, Delneste Y, et al. Histamine and prostaglandin E up-regulate the production of Th2-attracting chemokines (CCL17 and CCL22) and down-regulate IFN-gamma-induced CXCL10 production by immature human dendritic cells. Immunol. 2006;117:507-516.
19. Gutzmer R, Diestel C, Mommert S, Kother B, Stark H, Wittmann M, et al. Histamine H4 receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. J Immunol. 2005;174: 5224-5232. (Pubitemid 40593160)
20. Ling P, Ngo K, Nguyen S, Thurmond RL, Edwards JP, Karlsson L, et al. Histamine H4 receptor mediates eosinophil chemotaxis with cell shape change and adhesion molecule upregulation. Br J Pharmacol. 2004;142:161-171. (Pubitemid 38698205)
21. Hofstra CL, Desai PJ, Thurmond RL, Fung-Leung WP. Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther. 2003;305: 1212-1221.
22. + T cells. J Immunol. 2006;176:7062-7070.
23. Geba GP, Ptak W, Askenase PW. Topical tacrolimus and cyclosporine A differentially inhibit early and late effector phases of cutaneous delayed-type and immunoglobulin E hypersensitivity. Immunol. 2001;104:235-242. (Pubitemid 32989524)
24. Wiederrecht G, Lam E, Hung S, Martin M, Sigal N. The mechanism of action of FK-506 and cyclosporin A. Ann N Y Acad Sci. 1993;696:9-19.
25. Hultsch T, Rodriguez JL, Kaliner MA, Hohman RJ. Cyclosporin A inhibits degranulation of rat basophilic leukemia cells and human basophils. Inhibition of mediator release without affecting PI hydrolysis or Ca2+ fluxes. J Immunol. 1990:144: 2659-2664. (Pubitemid 20136672)
26. Hultsch T, Brand P, Lohmann S, Saloga J, Kincaid RL, Knop J. Direct evidence that FK506 inhibition of FcεRI-mediated exocytosis from RBL mast cells involves calcineurin. Arch Dermatol Res. 1998;290:258-263. (Pubitemid 28301552)
27. Park CW, Lee BH, Han HJ, Lee CH, Ahn HK. Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis. Br J Dermatol. 2005;152: 1173-1181.